|Bid||218.14 x 1000|
|Ask||218.20 x 1000|
|Day's Range||217.83 - 220.20|
|52 Week Range||144.75 - 222.59|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||23.35|
|Earnings Date||Oct 23, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||2.08 (0.95%)|
|1y Target Est||227.31|
Kevin Lobo, Chairman and Chief Executive Officer, will represent the Company in a presentation scheduled for 8:35 a.m. Eastern Time. A simultaneous webcast and replay of the Company's presentation will be available on Stryker's website at www.stryker.com. The webcast will be archived on the Investor Relations page of this site.
President and COO of Stryker Corp (30-Year Financial, Insider Trades) Timothy J Scannell (insider trades) sold 4,666 shares of SYK on 08/16/2019 at an average price of $217.08 a share. Continue reading...
Spencer S. Stiles will serve as Group President of Orthopaedics and Spine and will oversee Stryker’s Joint Replacement, Trauma & Extremities and Spine divisions. J. Andrew Pierce, Group President of MedSurg and Neurotechnology will oversee Stryker’s Instruments, Medical, Endoscopy, Sustainability and Neurotechnology businesses.
Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.
Allscripts (MDRX) second-quarter results gain from growth in bookings and solid show by client services segment. Contraction in operating margin remains a woe.
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
Cardinal Health (CAH) Q4 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, contraction in gross margin remains a concern.
We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.